In the evolving landscape of cancer careIn the evolving landscape of cancer care, the use of circulating tumor DNA (ctDNA),…
Browsing: Colorectal
On January 16, 2025, a significant advancement in cancer treatment was announced. The FDA approved a new therapeutic option for…
The GALAXY Study has provided compelling data that highlights the predictive value of circulating tumor DNA (ctDNA) status in colorectal…
…The field of oncology is continuously evolving, with research focusing on developing more effective and personalized treatment modalities. One such…
…In the rapidly evolving field of oncology, colorectal cancer (CRC) represents a significant area of research and clinical development. Innovations…
In a discussion on cancer science, Wassim Mchayleh, MD, explores the role of Minimal Residual Disease (MRD). Dr. Mchayleh discusses…
By. Fairooz F. Kabbinavar, MD, FACP​ Date. 12/06/2023 Fairooz F. Kabbinavar, MD, FACP, a medical oncologist with a background in…
By. Filippo Pietrantonio, MD Date: 11/14/2023 Clinical data from the study demonstrated the inhibition of feedback reactivation pathways with an…
Marwan Fakih, MD – City of Hope – FDA Approval of LONSURF in combination with Bevacizumab The FDA approval of…
MOASC – Spotlight on Oncology Colorectal Cancer AbstractsDate: August 12, 2023Location: Huntington Beach, CAPresenter: Jason A. Zell, DO, MPHPosition: Professor,…
Colorectal cancer is a growing concern, and its incidence among younger individuals, known as young-onset colorectal cancer (yoCRC), has been…
BRAF V600E colon cancer is a subtype of colorectal cancer characterized by a specific genetic mutation known as BRAF V600E.…
…Metastatic colorectal cancer (mCRC) continues to be a significant health challenge worldwide. Despite advancements in treatment methods, the prognosis for…
…The battle against cancer has led to a myriad of innovations in oncology, with each new breakthrough providing a beacon…
Rona Yaeger, MD, an eminent oncologist from Memorial Sloan Kettering Cancer Center, is currently involved in a significant clinical trial…
The phase 3 FRESCO-2 study evaluated the efficacy and safety of fruquintinib, a novel targeted therapy, in patients with advanced…
J. Randolph Hecht, MD from UCLA Health is conducting a phase 3 clinical trial called STELLAR-303 to evaluate the efficacy…
Dr. Suneel Kamath from the Cleveland Clinic – Young onset colorectal cancer (yoCRC) has been increasing over the past few…
Ethnic Minorities: Empowering to Increase Colorectal Cancer Screening Through Community Outreach Kimlin Ashing PhD By Kimlin Tam Ashing, PhDProfessor, Department…
SOX9: Can this protein enable a molecular reversal that could lead to colorectal cancer? Nilay Sethi MD By Nilay Sethi,…
Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David…
iFrame is not supported! Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase…
Geneoscopy: Evaluating the Efficacy of a Non-Invasive Colorectal Cancer Screening Test: Findings from the CRC-PREVENT Phase 3 Trial Dr. David…
iFrame is not supported! KRAS G12C Sotorasib: [2022] An Updated Overview in CRC Update On The CodeBreaK 100 Trial/KRAS…
KRAS G12C Sotorasib: [2022] An Updated Overview in CRC Update On The CodeBreaK 100 Trial/KRAS G12C Sotorasib The CodeBreaK…
UCSF With FDA In Robotic Colorectal Surgery Trial: da Vinci SP [2022] Â The da Vinci SP Surgical Systems So…
Question and Answer Session May Cho, MD – ASCO 2022 Colon Cancer In-Depth Slides: MOASC Spotlight Link https://oncologytube.com/v/41298 May Cho,…
ASCO 2022 Colon Cancer In-Depth Slides: MOASC Spotlight  May Cho, MD from UCI Health ASCO (American Society of Clinical…
GI Genius vs Standard Colonoscopy: Is it Better? Â Rosario Ligresti, MD, FASGE Speaks About The GI Genius Intelligent Endoscopy…
ASCO (American Society of Clinical Oncology) 2022 Colon Cancer Overview: MOASC Spotlight  Today I presented three clinical trials at…
NRG-GI008 (CIRCULATE-US) Colon Cancer Overview [2022] To watch Dr. Arvind Dasari discuss the NRG-GI008 presentation with slides, Click Here! NRG-GI008…
NRG-GI008 (CIRCULATE-US) Colon Cancer Overview [2022] To watch Dr. Arvind Dasari discuss the NRG-GI008 presentation with slides, Click Here! NRG-GI008…
FRESCO-2 Trial Met Primary Endpoints in Patients With Metastatic Colorectal announced HUTCHMED from the Fruquintinib Global Phase III Trial The…
We completed a geospatial epidemiological study, examining colorectal cancer mortality among those diagnosed before the age of 50. And this…
In this interview, I will present the results of a translational analysis of the Italian drug study. AtezoTRIBE is a…
Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology…
Heinz-Josef Lenz, MD, is a professor in the Departments of Medicine and Preventive Medicine in Keck School of Medicine’s oncology…
Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this audio, he speaks about the ASCO 2022…
Thomas George, MD, FACP, Professor, MD-Hematology/Oncology from UF Health Cancer Center. In this video, he speaks about the ASCO 2022…
Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt…
Richard Kim, MD, Professor, clinical and research interests focus on gastrointestinal tumors, in particular, hepatobiliary and colon cancer at Moffitt…
Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In…
Andrea Grace Bocobo, BS, Fourth-year medical student at Touro University California and Visiting Graduate Student at UCSF GI Oncology. In…
Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh…
Min Sun, MD, Ph.D., Oncologist, and Hematologist at UPMC Hillman Cancer Center, Clinical Assistant Professor at the University of Pittsburgh…
Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer…
Nageshwara Arvind Dasari, MD, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine at MD Anderson Cancer…
Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at…
Sue S. Yom, MD, Ph.D., Professor and Vice Chair, Strategic AdvisoryDepartment of Radiation Oncology; Professor, Otolaryngology-Head and Neck Surgery at…
Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale…
Michael Cecchini, MD, Assistant Professor of Medicine (Medical Oncology); Co-Director, Colorectal Program in the Center for Gastrointestinal Cancers at Yale…
Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in…
Federico Aucejo, MD, is the Director of the Liver Cancer Program and Surgical Director of the Liver Tumor Clinic in…
Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about…
Sarbajit Mukherjee, MD, MS, Assistant Professor, Gastrointestinal Medical Oncologist at Roswell Park Cancer Institute. In this video, he speaks about…
Gerard E Mullin, MD, MS, Associate Professor of Medicine at Johns Hopkins Medicine. In this video, he speaks about Study:…
Gerard E Mullin, MD, MS, Associate Professor of Medicine at Johns Hopkins Medicine. In this video, he speaks about Study:…
Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics…
Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics…
Thomas Abrams, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GI…
Thomas Abrams, MD, Assistant Professor of Medicine at Dana-Farber Cancer Institute. In this video, he speaks about the ASCO GI…
Susanna Ulahannan, MD, MMEd, Assistant Professor, Associate Director Phase 1 Unit at University Of Oklahoma Health Sciences Center. In this…
Susanna Ulahannan, MD, MMEd, Assistant Professor, Associate Director Phase 1 Unit at University Of Oklahoma Health Sciences Center. In this…
William Harris, MD, Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about…
William Harris, MD, Associate Professor, Clinical Research Division at Fred Hutchinson Cancer Research Center. In this video, he speaks about…
Professor Caio Max S. Rocha Lima, MD, M. Robert Cooper Professor in Medical Oncology, Co-leader GI Oncology and Co-leader Phase…
Mustafa Raoof, M.D., M.S., Surgical Oncologist at the City of Hope. In this video, he speaks about the ASCO GI…
Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic. In this video, he discusses the ASCO GI 2022 Abstract -…
Professor Caio Max S. Rocha Lima, MD, M. Robert Cooper Professor in Medical Oncology, Co-leader GI Oncology and Co-leader Phase…
Mustafa Raoof, M.D., M.S., Surgical Oncologist at the City of Hope. In this video, he speaks about the ASCO GI…
Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic. In this video, he discusses the ASCO GI 2022 Abstract -…
Erica K. Barnell, MD, Ph.D. Chief Science Officer at Geneoscopy. In this interview, she speaks about CRC-PREVENT: Clinical validation trial…
Erica K. Barnell, MD, Ph.D. Chief Science Officer at Geneoscopy. In this interview, she speaks about CRC-PREVENT: Clinical validation trial…
Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics…
Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics…
Joleen M. Hubbard, MD, Oncology Department, Mayo Clinic speaks about the ESMO 2021 Abstract – 507TiP – PRESERVE 1: A…
Rajesh Balkrishnan, BS, MS, Ph.D., Professor Department of Public Health Sciences, University of Virginia speaks about Associations between initiating antihypertensive…
Kana Wu, M.D., Ph.D., Principal Research Scientist in the Department of Nutrition at Harvard T. H. Chan School of Public…
Kana Wu, M.D., Ph.D., Principal Research Scientist in the Department of Nutrition at Harvard T. H. Chan School of Public…
David Illson, MD, Ph.D., Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College speaks…
Rajesh Balkrishnan, BS, MS, Ph.D., Professor Department of Public Health Sciences, University of Virginia speaks about Associations between initiating antihypertensive…
According to new research published in the January 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network, more than…
Emerens Wensink, MD, Ph.D. Candidate from University Medical Center Utrecht, Utrecht University discusses Survival of patients with deficient mismatch repair…
Cathy Eng, MD, FACP, FASCO from Vanderbilt-Ingram Cancer Center Vanderbilt University Medical Center speaks about the Editorial – BRAF Mutation…
Afsaneh Barzi, MD, medical oncologist at the City of Hope discusses the ASCO GI 2020 Discussion- Disparities in Access to…
Afsaneh Barzi, MD, medical oncologist at the City of Hope discusses the ASCO GI 2020 Abstract – Health-related quality of…
Jonathan Cheng, MD Merck – Vice President Clinical Research discusses KEYTRUDA Is the First Single-Agent, Anti-PD-1 Therapy Approved for the…
Scott Kopetz, MD at MD Anderson discusses the FDA Approval Encorafenib) In Combination With Cetuximab For The Treatment Of Brafv600E-Mutant…
Oliver Peacock, MD The University of Texas MD Anderson Cancer Center gives his final thoughts about his ASCO 2020 Abstract…
Oliver Peacock, MD The University of Texas MD Anderson Cancer Center answers common questions he has received for his ASCO…
Oliver Peacock, MD The University of Texas MD Anderson Cancer Center discusses his ASCO 2020 Abstract on Improving the AJCC/TNM…
Lindsey Rolfe at Clovis Oncology outlines a New Preclinical Data on ALKS 4230 in Combination With Lucitanib The research assessed…
Daniel Becker MD at NYU Langone discusses an ASCO 2020 abstract entitled Exploring the Cancer Genome Atlas (TCGA) for the…
Cathy Eng, MD at Vanderbilt University Medical Center discusses Anal cancer’s first randomized trial for inoperable disease sets the treatment…
Marian Navratil, P.h.D. of HTG Molecular Diagnostics discusses the power of RNA profiling now and in the future. This data…
Marian Navratil, P.h.D. of HTG Molecular Diagnostics discusses the future of RNA profiling and using it for detecting inflammation of…
Marian Navratil, P.h.D. of HTG Molecular Diagnostics How HGT is Different than RNAPlatform comparison of HTG EdgeSeq and RNA-Seq for…
Marian Navratil, P.h.D. of HTG Molecular Diagnostics gives an overview from ASCO 2020 the Platform comparison of HTG EdgeSeq and…
Kathryn Lang, MD – Guardant Health, is this available today. The data presented at the AACR 2020 show that the…
Kathryn Lang, MD of Guardant Health discusses Restricting Cohort to Negative Test Results with Liquid Biopsy Highly Accurate in Detecting…
Kathryn Lang, MD of Guardant Health provides an overview of data presented at AACR 2020 that shows that the LUNAR-2…
Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data…
Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data…
Heather Losey, Ph.D., Director, Program Lead in Immuno-Oncology and Jared Lopes, Ph.D., Principal Scientist – Alkermes discusses New Preclinical Data…
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil,…
Jeffrey A. Meyerhardt, MD, MPH, FASCO – Dana-Farber Cancer Institute discusses Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil,…
Liv Johannessen, P.h.D.Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models of…
Liv Johannessen, P.h.D. Syros Pharmaceuticals discusses Activity of SY-5609 an oral noncovalent potent and selective CDK7 inhibitor in preclinical models…
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of…
Marwan Fakih, MD of City of Hope discusses CodeBreak 100: activity of AMG 510, a novel small molecule inhibitor of…
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic…
Andre Thierry, MD of University Pierre et Marie Curie @UPMC discusses pembrolizumab vs. chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic…
Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai: how information is generated. A leading molecular science…
David Spetzler, MS of Caris Life Sciences @carisls discusses the MI FOLFAXai. A leading molecular science innovator focused on delivering…
A leading molecular science innovator focused on delivering on the promise of precision medicine, today announced the launch of MI…
Heinz-Josef Lenz, MD Professor of Medicine and Preventive Medicine Associate Director, Clinical Sciences J Terrence Lanni Chair in Cancer Research…
Earn CME: https://www.naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
Earn CME: https://naccme.com/program/19-gdugi-1 In this webcast from the ‘Metastatic Colorectal Cancer: An individualized Approach to Optimal Treatment Selection and Adverse…
Katherine Clifton @katherineclift4 of @WUSTL answers a common question regarding using an anti-EGFR resistance mechanism: are these gene fusions targetable?…
Katherine Clifton, MD @katherineclift4 of @WUSTL discusses actionable fusions as an anti-EGFR resistance mechanism. __________ Read here:Â https://ascopubs.org/doi/10.1200/PO.19.00141
Scott Kopetz, MD @skopetz of @MDAndersonNews discusses what’s next for the phase 3 BEACON trial in colorectal cancer. __________ Pfizer…
Scott Kopetz, MD @skopetz of @MDAndersonNews explains the phase 3 BEACON CRC trial. ______ Pfizer Inc. (NYSE: PFE) today announced…
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced detailed results from the interim analysis of the Phase 3 BEACON CRC…
Sudha Amarnath, MD of Cleveland Clinic discusses how this will affect treatment and clinicians today. _____ Preoperative pelvic radiation (XRT),…
Sudha Amarnath, MD of Cleveland Clinic answers: Is this truly safe? Are these outcomes real? _____ Preoperative pelvic radiation (XRT),…
Sudha Amarnath, MD of Cleveland Clinic discusses toxicity and efficacy outcomes of preoperative pelvic radiation therapy in patients with inflammatory…
Afsaneh Barzi, MD of Keck School of Medicine discusses the factors to consider in the IDEA collaboration.
Afsaneh Barzi, MD of Keck School of Medicine provides the impact the IDEA data will have on clinicians.
Afsaneh Barzi, MD of Keck School of Medicine explains IDEA collaboration findings in 3 versus 6 months for stage 3…
Afsaneh Barzi, MD of Keck School of Medicine presents the IDEA (International Duration Evaluation of Adjuvant Chemotherapy) collaboration which investigated…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center discusses the…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses molecular…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center addresses whether…
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center evaluates the…
Anders Rabbe CEO Of Isofol Medical Discusses Phase 3 AGENT Study: Primary Endpoint Is Response Rate, Tumor Shrinkage, & PFS…
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Support From FDA, Doctors Are Excited About The Drug & How It…
Anders Rabbe CEO Of Isofol Medical Discusses Arfolitixorin: Increases Efficacy Of Standard Of Care Chemotherapy.
Alexa Schrock PhD Of Foundation Medicine Discusses How To Act On TMB Score: Patients Might Need A Higher TMB To…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
Scott Kopetz M.D., PhD., FACP Associate Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of…
John Strickler, M.D. Assistant Professor Of Medicine At Duke Cancer Institute, Discusses The Importance Of Genomic Profiling In Treating Colorectal…
Raymond Wadlow, M.D. Medical Oncologist At Inova Fairfax Hospital Discusses Thoughts On CCTG CO.26 Canadian Study Demonstrating Immunotherapy Benefit In…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Howard Hochster, MD, Associate Director for Clinical Research, Rutgers Cancer institute of New jersey, Director of Oncology Research, RWJBarnabas Health…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Whether Regorafenib…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Genetic Testing…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Thoughts On…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, Managing 2nd…
Jeffrey A. Meyerhardt, MD, Professor, Medicine, Harvard Medical School Active Medical Staff, Medical Oncology, Dana-Farber Cancer Institute discusses, BEACON Study…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Use Of Regorafenib In The Management Of Advanced…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Patient Selection & Treatment Algorithms In 2nd And 3rd…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses The Role Of Circulating Tumor DNA (ctDNA). At The…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses CCTG CO.26 Trial In Advanced Refractory CRC Presented At…
Axel Grothey, MD, Consultant, West Cancer Center, University of Tennessee, Discusses Next Generation Sequencing And mCRC. At The 2019 Gastrointestinal…
Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF,…
Alan Venook, MD, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, Professor, Department of Medicine, UCSF,…
Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine,…
Richard Kim, MD, Gastrointestinal Oncology Department, Moffitt Cancer Center, Assistant Professor of Oncology, University of South Florida College of Medicine,…
Fa-Chyi Lee, MD, UC Irvine Health, talks about Adjuvant Chemotherapy for Rectal Cancer | Possibly Use Single-Agent Capecitabine at MOASC…
Fa-Chyi Lee, MD, UC Irvine Health, talks about a possible Better Approach in the Next 1-2 Years | For RAS…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Major Impact from HIPEC is Insurance Reimbursement | Insurance Companies Feel…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the Negative Results from HIPEC Study | Surgery May Still Have Role…
Yung Lyou, MD, UC Irvine Health, talks about 3 Clinical Trials in Non-Colorectal GI Cancers | REACH-2, KEYNOTE-061, PRODIGE 24…
Fa-Chyi Lee, MD, UC Irvine Health, talks about the HIPEC Study Requires Further Evaluation | Closed United States Intergroup Study…
Howard Hochster, MD, shares his perspective on the outcomes of the PRODIGY7 study in metastatic colorectal cancer patients using heated…
John Leighton, MD, shares his thoughts on the headline Immunotherapy Now Standard for Some Patients With Colorectal Cancer
Atrayee Basu Mallick, MD, shares the advances in the treatment of colorectal cancer
Howard Hochster, MD, weighs in on the VALENTINO study regarding the effectiveness of maintenance 5FU/LV following FOLFOX + panitumumab induction…
Atrayee Basu Mallick, MD, talks about how tumor-sidedness impacts her colorectal cancer (CRC) treatment algorithms at Annual Meeting 2018.
Howard Hochster, MD, explains the outcomes of the ECOG-7208 study in 2nd line metastatic colorectal cancer (mCRC) patients at Annual…
Atrayee Basu Mallick, MD, shares how nivolumab is being incorporated into metastatic colorectal cancer (mCRC) treatment algorithms at Annual Meeting…
John Leighton, MD, explains whether tumor sidedness impacts colorectal cancer treatment algorithms at Annual Meeting 2018.
Atrayee Basu Mallick, MD, shares her thoughts on the outcomes of the Checkmate 142 study looking ipilimumab and nivolumab in…
Atrayee Basu Mallick, MD, talks about the patient type and setting where vemurafenib has been added to the NCCN guidelines…
Atrayee Basu Mallick, MD, shares her thoughts on immunotherapy in colorectal cancer at Annual Meeting 2018.
Al Benson III, MD, FACP, explains how tumor-sidedness impacts colorectal cancer treatment algorithms.
Al Benson III, MD, FACP, explains the role of I-O and immunotherapy when treating colorectal cancer.
Dr. Benson, Professor of Medicine, Northwestern University, shares which molecular markers are most important when treating colorectal cancer patients.
Vicky Coyle, MD, of Queen’s University Belfast, Belfast, UK, spoke to us at the UK Oncology Forum (OF) 2018, held…
Aspirin has been suggested as a preventative measure for several cancer types, in particular colorectal cancer, as Vicky Coyle, MD,…
Kai-Keen Shiu, MRCP, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, speaks to us about future directions…
Scott Kopetz, M.D., Ph.D., FACP, discusses Safety Lead-In from the Beacon Study 48% Overall Response Rate
Scott Kopetz, M.D., Ph.D., FACP, explains Less Predictable Alternate BRAF Mutations Not all BRAF mutations are the same.
Scott Kopetz, M.D., Ph.D., FACP, discusses Getting Patients into Clinical Trial Sooner than Later Start with aggressive cytotoxic backbone
Scott Kopetz, M.D., Ph.D., FACP, explains the Rare Clones of KRAS Mutant Cells Able to identify resistant clones
Scott Kopetz, M.D., Ph.D., FACP, explains BRAF V600E Mutation BRAF with EGFR Provided Synergy.